OTCQB is the venture marketplace for companies that are current in their reporting with a U.S. regulator, making it easy for investors to identify companies that are current in their reporting obligations.
Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.
Link to Patent:
World's first US patented* technology to eliminate administration of incorrect medicinal substances by hypodermic needle.
Administering the right drug with the right dose to the right patient at the right time.
* Patent No. 7,347,841 B2 Granted on: March 25, 2008
Outstanding: 541 Million
Float: 388 Million
Market Cap (1/16/13): $1.1 Million
At least one medication error per hospital patient per day (Insititute of Medicine).
400,000 preventable drug related injuries per year.
Up to 98,000 Americans die each year due to medical errors by healthcare professionals.
Contact Information: Medisafe 1 Technologies Corp 216 Jaffa Street
Second Floor Tel: +972-2-5021322
Fax: +972-2-5021321 E-mail: